PLANO, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), will participate in the Piper Sandler 36th Annual Healthcare Conference, to be held Dec. 3 – 5 in New York City. Integer President and Chief Executive Officer Joseph Dziedzic is scheduled to present Tuesday, Dec. 3, 2024, at 10:30 a.m. EST. The presentation will be accessible via a live webcast. The link to the live webcast may also b ...

Integer Holdings (ITGR) witnessed strong momentum year to date. Shares of the company have gained 40.8% compared with the 6.7% rise of the industry in the same time frame. The S&P 500 Composite has risen 26.1% during the same period.With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment.Plano, TX-based Integer Holdings manufactures and develops medical devices and components primarily for original equi ...

PLANO, Texas, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization (CDMO), today announced the completion of the previously announced sale of its Electrochem business to Ultralife Corporation for $50 million in cash. Integer will use the proceeds from the sale to pay down outstanding debt. “With the divestiture of Electrochem, Integer is now a pure-play medical technology company with additional capital to d ...

Integer Holdings Corporation (ITGR) delivered adjusted earnings per share (EPS) of $1.43 in the third quarter of 2024, which improved 10.9% year over year. The figure topped the Zacks Consensus Estimate by 5.15%.The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others.GAAP EPS for the quarter was $1.01, reflecting an improvement of 21.7% year over year.Stay up-to-date with all quarterly releases: See Zacks Earnings Ca ...

财务数据和关键指标变化 - 第三季度销售额为4.31亿美元，同比增长9%，年初至今销售额为12.67亿美元，同比增长10% [6][10][8] - 调整后的营业收入同比增长17%，年初至今调整后的营业收入增长23% [6][9] - 调整后的净收入为5000万美元，同比增长11% [11] - 调整后的每股收益为1.43美元，同比增长21% [11][12] 各条业务线数据和关键指标变化 - 心血管产品线在过去四个季度的销售额同比增长15% [11] - 心脏节律管理和神经调节产品线在过去四个季度的销售额同比增长7% [11] - 心血管产品线的增长主要得益于电生理和结构性心脏的新产品 [11] 各个市场数据和关键指标变化 - 预计2024年销售额将增长10%至11%，有机增长率为7%至8% [14][15] - 新兴市场的客户需求强劲，预计将推动第四季度的销售增长 [22][28] 公司战略和发展方向和行业竞争 - 公司计划通过剥离非医疗业务，专注于医疗技术领域，预计将产生5000万美元的现金流 [7] - 公司目标是实现销售增长超过市场200个基点，调整后的营业收入增长速度是销售增长的两倍 [19][15] 管理层对经营环境和未来前景的评论 - 管理层对未来的展望持乐观态度，预计将继续实现强劲的销售增长和利润增长 [19][6] - 管理层提到，尽管面临一些短期挑战，如飓风影响，但整体业务表现良好，预计第四季度将恢复增长 [20][29] 其他重要信息 - 公司在第三季度的运营现金流为7200万美元，同比增长14% [13] - 净总债务为10.55亿美元，较第二季度减少4100万美元 [14] 问答环节所有提问和回答 问题: 关于第三季度有机增长趋势的变化 - 管理层表示，第三季度的有机增长率为4%，主要受到心脏节律管理产品线需求下降和飓风影响的影响 [20][21] 问题: 关于新任高管的角色变化 - 管理层强调新任高管将继续执行公司的战略，推动销售增长和利润增长 [24] 问题: 关于电生理业务的增长趋势 - 管理层表示，电生理业务仍在持续增长，预计将继续受益于新产品的推出 [26][27] 问题: 关于第四季度的有机增长加速预期 - 管理层预计第四季度的有机增长将加速，特别是在心血管和神经调节产品线 [28] 问题: 关于飓风影响的持续性 - 管理层指出，飓风的影响主要是成本压力，预计不会对第四季度的销售产生重大影响 [29] 问题: 关于2025年的市场预期 - 管理层表示，预计2025年将继续保持正常的市场增长，目标是实现有机增长超过市场200个基点 [32]

Integer (ITGR) reported $431.42 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 6.6%. EPS of $1.43 for the same period compares to $1.27 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $443.19 million, representing a surprise of -2.66%. The company delivered an EPS surprise of +5.15%, with the consensus EPS estimate being $1.36.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall S ...

业绩总结 - 2024年第三季度销售额为17.07亿至17.27亿美元，同比增长9%[5] - 调整后营业收入同比增长17%，预计2024年调整后营业收入为2.8亿至2.88亿美元，同比增长18%至22%[5] - 调整后每股收益（EPS）为5.24至5.43美元，同比增长14%至18%[5] - 自由现金流预计为9000万至1亿美元，同比增长49%至65%[5] - 2024年第三季度销售额同比增长9%，年初至今增长10%[27] - 调整后的营业收入同比增长17%，年初至今增长23%[27] - 调整后的每股收益（EPS）同比增长11%，年初至今增长21%[27] - 2024年第三季度净收入为36,282千美元，较2023年同期增长了约8.5%[58] - 2024年截至目前的净收入为107,876千美元，较2023年同期增长了约12.0%[59] 用户数据 - 2024年第三季度债务杠杆比率为3.0x，处于战略目标的中位数范围内[5] - 2024年有效税率预计在18.0%至19.0%之间[35] - 2024年第一季度有效税率为19.5%[56] - 2024年第二季度有效税率为19.5%[57] 未来展望 - 2024年销售额预计增长10%至11%，调整后营业收入和每股收益的中位数上调[5] - 2024年有机销售增长预计为7%至8%[24] - 2024年预计第四季度销售额将较第三季度增长，受新产品推出和客户增长推动[24] - 公司预计2024年整体销售将受到新产品和市场需求的推动[48] 新产品和新技术研发 - 预计2024年Cardio & Vascular产品线的销售将实现低双位数的同比增长[48] - 预计2024年CRM & Neuromodulation产品线的销售将实现高单位数的同比增长[51] - 2024年Advanced Surgical & Orthopedics产品线的销售将同比下降约个位数[53] 财务数据 - 2024年第一季度销售额为407,796千美元，较2023年同期的364,671千美元增长11.8%[56] - 2024年第一季度毛利为108,273千美元，毛利率为26.6%[56] - 2024年第一季度运营收入为69,572千美元，运营利润率为17.1%[56] - 2024年第二季度销售额为427,886千美元，较2023年同期的389,678千美元增长9.8%[57] - 2024年第二季度毛利为117,377千美元，毛利率为27.4%[57] - 2024年第二季度运营收入为62,883千美元，运营利润率为14.7%[57] - 2024年第三季度销售额为431,417千美元，同比增长8.7%[58] - 2024年第三季度毛利为116,568千美元，毛利率为27.0%[58] - 2024年第三季度运营收入为58,557千美元，运营利润率为13.6%[58] - 2024年截至目前的销售额为1,267,099千美元，同比增长10.1%[59] - 2024年截至目前的毛利为342,218千美元，毛利率为27.0%[59] - 2024年截至目前的运营收入为191,012千美元，运营利润率为15.0%[59] - 2024年截至目前的稀释每股收益为0.95美元，较2023年同期增长了约8.0%[59]

Integer (ITGR) came out with quarterly earnings of $1.43 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.15%. A quarter ago, it was expected that this medical device outsource manufacturer would post earnings of $1.24 per share when it actually produced earnings of $1.30, delivering a surprise of 4.84%.Over the last four qu ...

EXHIBIT 99.1 Integer Holdings Corporation Reports Third Quarter 2024 Results ~ Continued strong performance with 3Q24 financial results ~ ~ Raising midpoint of 2024 operating profit and EPS outlook ~ PLANO, Texas, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three and nine months ended September 27, 2024. Our previously announced sale of the Electrochem business for $50 million in cash remains on track and is expected to close later this month. E ...

Wall Street analysts expect Integer (ITGR) to post quarterly earnings of $1.36 per share in its upcoming report, which indicates a year-over-year increase of 7.1%. Revenues are expected to be $443.19 million, up 9.5% from the year-ago quarter.The consensus EPS estimate for the quarter has undergone an upward revision of 0.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a comp ...